Management of hepatitis B virus reactivation due to treatment of COVID-19

Terry Cheuk-Fung Yip1,2,3 · Madeleine Gill4,5 · Grace Lai-Hung Wong1,2,3 · Ken Liu4,5,6

Received: 12 December 2021 / Accepted: 25 January 2022 / Published online: 2 March 2022
© Asian Pacific Association for the Study of the Liver 2022

Abstract
The world has made significant progress in developing novel treatments for COVID-19 since the pandemic began. Some treatments target the patient’s dysregulated inflammatory response during COVID-19 infection and may cause hepatitis B reactivation (HBVr) in patients with current or past hepatitis B virus (HBV) infection. This review summarizes the risk and management of HBVr due to different treatments of COVID-19 in patients who have current or past HBV infection. Abnormal liver function tests are common during COVID-19 infection. Current evidence suggests that current or past HBV infection is not associated with an increased risk of liver injury and severe disease in COVID-19 patients. Among patients who received high-dose corticosteroids, various immunosuppressive monoclonal antibodies and inhibitors of Janus kinase, the risk of HBVr exists, especially among those without antiviral prophylaxis. Data, however, remain scarce regarding the specific use of immunosuppressive therapies in COVID-19 patients with HBV infection. Some results are mainly extrapolated from patients receiving the same agents in other diseases. HBVr is a potentially life-threatening event following profound immunosuppression by COVID-19 therapies. Future studies should explore the use of immunosuppressive therapies in COVID-19 patients with HBV infection and the impact of antiviral prophylaxis on the risk of HBVr.

Keywords SARS-CoV-2 · COVID-19 · Hepatitis B virus · Reactivation · Immunosuppression · Corticosteroids · Tocilizumab · Tofacitinib · Baricitinib · Sarilumab

Introduction
Coronavirus disease 2019 (COVID-19) is caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) which is highly infectious. To date, there have been over 240 million people infected globally resulting in 4.9 million deaths [1]. Consequently, COVID-19 was declared a pandemic by the World Health Organization (WHO) in March 2020. As it is so widespread, many
patients with COVID-19 also have concomitant chronic diseases. One such disease is chronic hepatitis B infection (CHB), which affects 257 million people worldwide [2]. In addition to those with current hepatitis B virus (HBV) infection (hepatitis B surface antigen [HBsAg]-positive), there are a further two billion people worldwide with past or resolved HBV infection (HBsAg-negative with anti-hepatitis B core antibody [HBc]-positive) [2]. The prevalence of CHB and cumulative number of cases of COVID-19 cases in each world region are displayed in Table 1. The prevalence of CHB in large COVID-19 studies has been reported to range from 0.8 to 6.3% [3–8] in Asia, compared with 0.1% in a large study from the United States (US) [9].

Since the COVID-19 pandemic began, the world has seen rapid developments in therapies which has led to the introduction of multiple effective vaccines. At the same time, the treatment approach to hospitalized adults with COVID-19 has also evolved [10]. These treatments can be divided into two main categories: those directed against the SARS-CoV-2 virus itself and those directed against the patient’s dysregulated inflammatory response to the virus. The immunosuppressive treatments in the latter category have the potential to cause hepatitis B reactivation (HBVr) in patients with current or past HBV infection [11]. This occurs because the host immune response is responsible for both control of viral replication and inflammatory liver injury. Attenuation of host immunity against HBV during immunosuppressive treatments can lead to increased HBV replication and hepatocyte expression of HBV antigen [12]. When the immunosuppressive treatment is later withdrawn, the host immune system reconstitutes in the presence of heavily HBV antigen-laden hepatocytes resulting in an enhanced immune response against HBV and subsequent liver injury.

In this review, we summarize the current knowledge of the impact of COVID-19 in patients with current or past HBV infection and evaluate the risk of HBVr with current recommended COVID-19 immunosuppressive treatments. We also make recommendations on antiviral prophylaxis for these patients.

### Current recommended treatments for hospitalized COVID-19 patients

Patients with mild (and even moderate) COVID-19 disease are often managed at home in many parts of the world. Hospitalization is usually reserved for patients with severe COVID-19 disease, which is more commonly observed in people aged ≥60 years, those living in nursing homes or long-term care facilities, and those with chronic medical conditions [10]. In an analysis of more than 615,000 laboratory-confirmed cases reported in the US between April and July 2021, 6.2% of patients required hospitalization, and 1.1% died [13]. People with reported medical conditions (45.4%) were six times more likely to be hospitalized for COVID-19 disease than those without medical conditions (7.6%) [14].

Hospitalized patients who do not require supplementary oxygen are generally managed with supportive care. Most experts recommend against the use of dexamethasone or other corticosteroids in such patients. If patients require oxygen therapy, remdesivir (an antiviral RNA polymerase inhibitor), dexamethasone, or their combination may be considered [15]. In patients with more severe COVID-19 disease requiring escalating supplemental oxygen or non-invasive ventilation, intravenous (IV) tocilizumab (a humanized monoclonal antibody against the interleukin-6 receptor [IL-6R]) or baricitinib (inhibitor of Janus kinase [JAK]) may be added to dexamethasone, with or without remdesivir [16–18]. Therefore, critically ill patients who require invasive mechanical ventilation or even extracorporeal membrane oxygenation may be given very potent immunosuppressive therapy by combining dexamethasone and IV tocilizumab (or alternatively sarilumab, another monoclonal antibody against IL-6R) [19]. The basis of these recommendations comes from the RECOVERY and REMAP-CAP trials which provide consistent evidence that tocilizumab, when administered with corticosteroids, offers a modest mortality benefit in some patients with COVID-19 who are severely ill, rapidly deteriorating with increasing oxygen needs, and have a significant inflammatory response [17, 19]. If tocilizumab or sarilumab are unavailable or not feasible, tofacitinib (another JAK inhibitor) has been recommended since it has also been shown to reduce death or respiratory failure in hospitalized patients with COVID-19 [20]. Furthermore, JAK inhibitors, particularly baricitinib, have theoretical direct antiviral activity through interference with viral endocytosis, and hence potentially prevent the entry of SARS-CoV-2 into susceptible cells [21].

### Table 1 Prevalence of CHB and COVID-19 cases by WHO region

| WHO Region       | Estimated prevalence of CHB (%)† | Number of cumulative COVID-19 cases (millions)‡ |
|------------------|---------------------------------|-----------------------------------------------|
| Africa           | 6.1                             | 6                                             |
| Americas         | 0.7                             | 92                                            |
| Eastern Mediterranean | 3.3                        | 16                                            |
| Europe           | 1.6                             | 73                                            |
| South-East Asia  | 2.0                             | 43                                            |
| Western Pacific  | 6.2                             | 9                                             |
| Global           | 3.5                             | 240                                           |

HBV = hepatitis B virus

†Data from WHO Global Hepatitis Report 2015 [2]
‡Data from WHO Weekly Epidemiological Update Oct 2021 [1]
Impact of COVID-19 infection on patients with CHB

Abnormal liver function tests (hepatocellular, cholestatic or mixed), are commonly observed among patients infected by SARS-CoV-2 [22]. Previous studies suggest that alanine aminotransferase (ALT) and aspartate aminotransferase (AST) elevations are observed in about 20% of COVID-19 patients [23–25] with AST levels often higher than ALT during the course of the disease [26]. The cause of this LFT pattern is not fully elucidated but does not appear to be related to muscle breakdown or hepatic ischemia. Elevated gamma-glutamyl transferase (GGT) and total bilirubin are reported in 23% and 1%–18% of patients, respectively, while elevation of alkaline phosphatase (ALP) is less common, occurring in 2%–5% of patients [23–25]. Multiple studies have shown that abnormal liver function tests are associated with a higher risk of progressing to severe COVID-19, including acute respiratory distress syndrome, the need for intensive care unit admission, and mortality [24, 25, 27, 28]. Moreover, the presence of liver cirrhosis is also shown to be associated with higher COVID-19-related mortality [29, 30].

Early studies with small sample sizes reported conflicting results on the impact of HBV infection on COVID-19. A report on 105 COVID-19 patients with CHB showed that liver injury was associated with mortality. In particular, death due to acute-on-chronic liver failure occurred in 4/14 COVID-19 patients with CHB who suffered from liver injury [8]. However, other studies showed no difference in clinical outcomes or even fewer adverse clinical outcomes in COVID-19 patients with CHB, compared to those without CHB [3, 31–33]. Most recently, a study from Hong Kong investigated the risk of COVID-19-related mortality in 353 patients with current and 359 with past HBV infection [4]. This study showed that liver injury, but neither current nor past HBV infection, is associated with COVID-19-related mortality. A study of 267 COVID-19 patients with CHB from the Korean nationwide insurance database also demonstrated no association between HBV infection and severe COVID-19 disease or mortality. Clinical outcomes did not differ between CHB patients with and without HBV antiviral treatment [34]. Data on the long-term outcomes after recovery of COVID-19 patients with CHB remain scarce. Future studies need to explore the impact of HBV antiviral agents on the clinical outcomes of COVID-19 patients with CHB, and the long-term outcome of these patients.

The exact mechanisms underlying liver injury in COVID-19 patients with pre-existing CHB can be multifactorial and hard to delineate. On top of the pre-existing HBV-induced liver disease, some additional pathogenses of liver injury in COVID-19 patients include direct infection of the liver by SARS-CoV-2, dysregulated host inflammatory response, HBVr, as well as the changes in hemodynamic and oxygen delivery in critically ill patients [23]. Drug-induced liver injury from COVID-19 treatments (e.g. remdesivir, favipiravir and tocilizumab) has also been reported [35]. Furthermore, abnormal liver function tests have been linked to a higher SARS-CoV-2 viral load during the early phase of infection, which may suggest direct viral damage to the liver early in the disease [36]. In contrast, the difference in viral load between patients with and without ALT/AST elevation is less obvious in later phases of the infection, which implies the involvement of immune-mediated pathways during viral clearance and/or other indirect pathways and the persistently high viral load in the late-onset liver injury [36, 37]. Moreover, ALT/AST elevation is associated with prolonged viral persistence of SARS-CoV-2 [36].

COVID-19 vaccination can protect CHB patients from severe COVID-19 and associated liver injury. Thus, the Global Hepatology Society, which includes the American Association for the Study of the Liver (AASLD), European Association for the Study of the Liver (EASL), Latin American Association for the Study of the Liver (ALEH), and Asian Pacific Association for the Study of the Liver (APASL), strongly recommend that all patients with liver disease (including CHB) discuss COVID-19 vaccination with their health care providers [38].

Impact of COVID-19 treatments on HBVr–Corticosteroids

Data from COVID-19 studies

The systemic corticosteroids used in hospitalized patients with severe COVID-19 disease are usually high-dose (dexamethasone 6 mg daily or equivalent) which increases the risk of HBVr, even if administered just for a few days [39]. Hence, routine testing for HBV serology (HBsAg, anti-HBc, and antibodies to HBsAg [anti-HBs]) is recommended in all individuals prior to commencing COVID-19 immunosuppressive treatments.

A Spanish COVID-19 study investigated 72 patients with current or past HBV infection among whom 41% received high-dose corticosteroids alone or in combination with other immunomodulators [40]. The study reported that 0/3 CHB patients and 0/29 HBsAg-negative, anti-HBc-positive patients who received nucleos(t)ide (NA) prophylaxis while on corticosteroids developed HBVr. One (4.5%) out of 22 HBsAg-negative, anti-HBc-positive patients without NA prophylaxis had detectable HBV DNA (< 10 IU/mL, without HBsAg seroreversion) after receiving corticosteroids. Our study from Hong Kong also reported 0/10 COVID-19 patients with CHB who received dexamethasone or hydrocortisone developed HBVr under NA prophylaxis (Table 2)
The impact of COVID-19 on patients with past HBV infection is not well elucidated, as only a minority of COVID-19 patients have had anti-HBc checked. Based on our aforementioned study in Hong Kong that described the COVID-19 patients with past HBV infection, there is no evidence that past HBV infection increases the risk of liver injury or mortality [4]. The risk of HBVr in patients with past HBV infection is even more difficult to establish but is generally believed to be low-moderate (<10%). Nevertheless, there is theoretically still a risk of HBVr if the immunosuppression is profound enough, either because of the COVID-19 therapies or by the COVID-19 disease. Hence a high index of suspicion is warranted and monitoring for HBVr should be performed in these patients.

Data from non-COVID-19 studies

Corticosteroids are the most widely used immunosuppressive agents for a wide spectrum of acute and chronic inflammatory diseases, including rheumatological diseases, other immune-mediated diseases such as inflammatory bowel disease (IBD), respiratory and renal diseases, anaphylaxis, and so on [41]. Short courses of corticosteroids were believed to be safe in CHB patients, even in the presence of disease-modifying anti-rheumatic drugs (DMARDs), yet an increase in serum HBV DNA level was observed in patients who were also exposed to biologic agents [42]. The degree of immunosuppression increases with dose and duration of corticosteroids. A prednisolone 20 mg daily or more (i.e. dexamethasone ≥ 3 mg daily) for longer than 2 weeks is considered clinically significant immunosuppression and high risk (>10%) of HBVr in HBsAg-positive patients. However, this duration of corticosteroids remains arbitrarily defined, as our recent real-world cohort study showed that shorter courses (<7 days) of high-dose corticosteroids might still increase the risk of HBVr flare [43].

Patients with past HBV infection are at moderate risk (1–10%) of HBVr after corticosteroid therapy with an annual risk of 1.8% [44]. However, high peak daily dose of corticosteroid equivalent to >40 mg prednisolone such as doses used in COVID-19 (i.e. dexamethasone >6 mg daily), regardless of duration of therapy, can increase the risk for hepatitis flare by 2–3 times in HBsAg-negative, anti-HBc-positive patients [44].

Impact of COVID-19 treatments on HBVr–Non-corticosteroid drugs

As aforementioned, various immunosuppressive monoclonal antibodies and JAK inhibitors have emerged as important agents in the management of COVID-19. Prior to COVID-19, these drugs have primarily been used in treatment of rheumatological conditions, particularly rheumatoid arthritis (RA). Therefore, while the HBVr experience with these drugs is limited in COVID-19, previous rheumatology literature provides some guidance.

Tocilizumab

By blocking IL-6R, tocilizumab attenuates the cytokine storm of severe COVID-19 which is mediated by IL-6. However, IL-6 has been shown to hinder HBV replication at the transcription level and its inhibition may increase the risk of HBVr in infected individuals [45]. In the only study of HBVr among hospitalized COVID-19 patients undergoing tocilizumab treatment, the outcomes of 44 HBsAg-negative, anti-HBc-positive patients were described [40]. Over half (61%) of these patients received prophylactic entecavir prior to tocilizumab treatment. After a short follow-up of only 1–2 months, no patients experienced HBsAg seroreversion while 1/17 (5.9%) patients not receiving NA prophylaxis developed detectable HBV DNA, but below the quantification limit (<10 IU/mL) with normal ALT after a single dose of tocilizumab.

More data on HBVr following tocilizumab therapy exist from its established use in RA. Case reports of serious and even fatal HBV flares in HBsAg-positive patients with RA after tocilizumab have been described [46, 47]. As such antivirals are often commenced in these patients prior to treatment, thus limiting their representation in the literature. Only two tocilizumab studies have described HBsAg-positive patients (combined n = 16) [40, 48–50]. Of these, 6/10 (60%) developed HBVr in those who did not receive NA prophylaxis (usually due to patient choice) compared to 0/6 in those who did. Of the six HBVr cases, three had virological reacti- reactivations with normal ALT while three had biochemical flares (ALT 150–950 U/L) including two patients with jaundice. All received antiviral therapy and recovered from their HBVr. Therefore, there is a high risk (>10%) of HBVr after tocilizumab in HBsAg-positive patients with ALT elevation and jaundice seen in 50% and 33%, respectively.

Regarding HBsAg-negative, anti-HBc-positive patients, a recent systematic review identified eight observational cohorts (almost all with past HBV infection) receiving tocilizumab [51]. These studies revealed the HBVr rate among HBsAg-negative, anti-HBc-positive patients (albeit using slightly different definitions) ranged from 0 to 11.1% with a pooled rate of 5/192 (2.6%) in those not taking prophylaxis and 0/42 (0%) in those taking NA prophylaxis. Therefore, there appears to be a moderate (1–10%) risk of HBVr following tocilizumab in HBsAg-negative, anti-HBc-positive patients. Compared with HBsAg-positive HBVr, the severity of these
Table 2  Studies on HBV reactivation in patients treated with immunosuppressive therapy

| Studies (Location and year) | Indication | Definition of HBVr used                                                                                                         | Median/mean follow-up duration | HBV reactivation in HBsAg + patients | HBV reactivation in HBsAg-/anti-HBc + patients |
|-----------------------------|------------|--------------------------------------------------------------------------------------------------------------------------------|-------------------------------|---------------------------------------|-------------------------------------------------|
| **Dexamethasone** Recommended dose in COVID-19: 6 mg IV or PO daily for up to 10 days† | Yip et al. [4] (Hong Kong, 2021) | HBsAg +: > 1 log₁₀ increase in HBV DNA compared with baseline level                                                            | 13 days                       | 0/8 (0%) with prophylaxis                      | Not studied                                     |
| **Methylprednisolone** Recommended dose in COVID-19: 32 mg IV or PO daily for up to 10 days† | Rodriguez-Tajes et al. [40] (Spain, 2021) | HBsAg +: not defined; HBsAg-/anti-HBc +: detectable HBV DNA or HBsAg seroreversion‡                                                | 1–2 months after last dose     | 0/3 (0%) with prophylaxis                      | 1/22 (4.5%), 0/29 (0%) without prophylaxis      |
| Braun-Moscovici et al. [42] (Israel, 2016) | Rheumatic diseases (mostly RA) | HBsAg + or HBsAg-/anti-HBc +: elevation of ALT three times or more the upper limit of normal and/or > 1 log₁₀ increase of HBV DNA compared with baseline level | 4.8 years                     | 0/7 (0%) without prophylaxis and concomitant immunosuppressive therapy; 4/9 (44.4%) without prophylaxis and received concomitant DMARDs and/or prednisone | 0/1 (0%) without prophylaxis; 1/3 (33.3%) without prophylaxis and received concomitant DMARDs and/or prednisone |
| **Prednisolone** Recommended dose in COVID-19: 40 mg IV or PO daily for up to 10 days† | Wong et al. [43] (Hong Kong, 2019) ¶ | HBsAg +: > 1 log₁₀ increase in HBV DNA compared with baseline level                                                              | 1 year                        | 303/678 (44.7%) without prophylaxis            | Not studied                                     |
| Wong et al. [44] (Hong Kong, 2020) ¶ | Not specified | HBsAg-/anti-HBc +: HBsAg seroreversion                                                                                              |                               | 28/502 (5.6%) without prophylaxis              |                                                 |
| **Hydrocortisone** Recommended dose in COVID-19: 160 mg IV or PO daily for up to 10 days† | Yip et al. [4] (Hong Kong, 2021) | HBsAg +: > 1 log₁₀ increase in HBV DNA compared with baseline level                                                              | 13 days                       | 0/2 (0%) with prophylaxis                      | Not studied                                     |
| **Tocilizumab** Recommended dose in COVID-19: 8 mg/kg (up to 800 mg) single IV dose | Rodriguez-Tajes et al. [40] (Spain, 2021) | HBsAg +: not defined; HBsAg-/anti-HBc +: detectable HBV DNA or HBsAg seroreversion‡                                               | 1–2 months after last dose     | 0/3 (0%) with prophylaxis                      | 1/17 (5.9%), 0/27 (0%) without prophylaxis      |
| Studies (Location and year) | Indication | Definition of HBVr used | Median/mean follow-up duration | HBV reactivation in HBsAg + patients | HBV reactivation in HBsAg-/anti-HBc + patients |
|---------------------------|------------|-------------------------|-------------------------------|--------------------------------------|-----------------------------------------------|
| Kuo et al. [49] (Taiwan, 2021) | RA         | HBsAg +: > 2 log₁₀ increase in HBV DNA compared with baseline level OR HBV DNA > 3 log₁₀ IU/mL if previously undetectable HBV DNA OR absolute HBV DNA > 4 log₁₀ IU/mL if baseline value unavailable‡ | 9 years                       | 3/3 (100%) without prophylaxis             | 1/64 (1.6%) without prophylaxis               |
| Serling-Boyd et al. [60] (US, 2021) | RA         | HBsAg-/anti-HBc +: detectable HBV DNA OR HBsAg seroreversion‡ | 4 years                       | Not studied                           | 0/12 (0%) without prophylaxis                 |
| Nakamura et al. [71] (Japan, 2019) | RA         | HBsAg-/anti-HBc +: > 1 log₁₀ increase or absolute increase of 5 log₁₀ copies/mL in HBV DNA compared with baseline level OR HBsAg seroreversion | 1.5 years                     | Not studied                           | 2/18 (11.1%) without prophylaxis               |
| Lin et al. [72] (Taiwan 2019) | RA         | No definition provided                                 | 3 years                       | Not studied                           | 0/11 (0%) without prophylaxis                 |
| Watanabe et al. [73] (Japan, 2019) | RA         | HBsAg-/anti-HBc +: detectable HBV DNA                  | 1.25 years                    | Not studied                           | 1/25 (4.0%) without prophylaxis                |
| Ahn et al. [74] (Korea, 2018) | RA         | HBsAg-/anti-HBc +: detectable HBV DNA                  | 10.8 months                   | Not studied                           | 0/15 (0%) without prophylaxis                  |
| Chen et al. [48] (China, 2017) | RA         | All: > 2 log₁₀ increase in HBV DNA compared with baseline level OR detectable HBV DNA OR HBsAg or HBeAg seroreversion | 3 months                      | 3/5 (60.0%) without prophylaxis             | 0/41 (0%) without prophylaxis                   |
| Chen et al. [50] (Taiwan, 2017) | RA         | HBsAg +: > 1 log₁₀ increase in HBV DNA compared with baseline level OR HBV DNA > 3 × increase in ALT level with HBV DNA > 20,000 IU/mL if baseline value unavailable | 28.1 months                   | 0/2 without prophylaxis                     | Not studied                                    |
| Mok et al. [75] (Hong Kong, 2014) | RA         | No definition provided                                 | 1.3 years                     | Not distinguished from past HBV         | 0/159 (0%) without prophylaxis                  |
Table 2 (continued)

| Studies (Location and year) | Indication | Definition of HBVr used | Median/mean follow-up duration | HBV reactivation in HBsAg + patients | HBV reactivation in HBsAg-/anti-HBc + patients |
|----------------------------|------------|-------------------------|--------------------------------|--------------------------------------|-----------------------------------------------|
| **Tofacitinib**<br>Recommended dose in COVID-19: 10 mg PO twice daily for up to 14 days† | RA | HBsAg +: > 2 log₁₀ increase in HBV DNA compared with baseline level OR HBV DNA > 3 log₁₀ IU/mL if previously undetectable HBV DNA OR absolute HBV DNA > 4 log₁₀ IU/mL if baseline value unavailable‡ | Unclear | 2/6 (33.3%) without prophylaxis 0/2 (0%) with prophylaxis | 2/64 (3.1%) without prophylaxis |
| Wang et al. [61] (Taiwan, 2021) | RA | HBsAg-/anti-HBc +: detectable HBV DNA OR HBsAg seroreversion‡ | 3.1 years | Not studied | 0/4 (0%) without prophylaxis 0/2 (0%) with prophylaxis |
| Serling-Boyd et al. [60] (US, 2021) | RA | HBsAg-/anti-HBc +: > 1 log₁₀ increase or absolute increase of 5 log₁₀ copies/mL in HBV DNA compared with baseline level OR HBsAg seroreversion | 3–6 months after last dose | 2/4 (50.0%) without prophylaxis 0/2 (0%) with prophylaxis | 0/75 (0%) without prophylaxis |
| Chen et al. [59] (Taiwan, 2018) | RA | All: > 2 log₁₀ increase in HBV DNA cases with baseline level | 2.4 years | Not studied | 4/215 (1.9%) without prophylaxis But 32/215 (14.9%) if using detectable HBV DNA as definition of HBVr |
| **Baricitinib**<br>Recommended dose in COVID-19: 1–4 mg PO daily depending on eGFR for up to 14 days† | COVID-19 | HBsAg +: not defined HBsAg-/anti-HBc +: detectable HBV DNA or HBsAg seroreversion | 1–2 months after last dose | Not studied | 0/2 (0%) without prophylaxis |
| Rodriguez-Tajes et al. [40] (Spain, 2021) | RA | HBsAg+/anti-HBc+: ≥ 2 log increase from baseline levels or new appearance of HBV DNA to a level of ≥ 100 IU/mL§ | 2.4 years | Not studied | 4/215 (1.9%) without prophylaxis But 32/215 (14.9%) if using detectable HBV DNA as definition of HBVr |

ALT = alanine aminotransferase, anti-Hbc = antibody to hepatitis B core antigen, HBeAg = hepatitis B e antigen, HBsAg = hepatitis B surface antigen, HBV = hepatitis B virus, HBVr = hepatitis B virus reactivation, RA = rheumatoid arthritis

†Or until hospital discharge
‡American Association for the Study of Liver Diseases guidelines definition [64]
§Asian Pacific clinical practice guidelines definition [12, 65]
¶All steroid uses were standardized to prednisolone equivalent dose
reactivations was milder as 4/5 cases had re-emergence of detectable HBV DNA at low levels (< 20 IU/mL), no HBsAg seroreversion, normal ALT levels, and no need for antiviral therapy.

Large pooled studies of HBsAg-negative/anti-HBc-positive patients receiving biologic agents (including tocilizumab) have identified no anti-HBs to be an independent risk factor for HBVr [52–54]. Therefore, anti-HBs titres may be used to further sub-stratify HBVr risk in patients with past HBV infection. However, more data are needed before recommendations can be made for specific agents.

**Sarilumab**

Sarilumab is an alternative IL-6R for COVID-19 if tocilizumab is not available or feasible to use [19]. There are currently no data on HBVr following sarilumab in either COVID-19 or RA patients. Since both drugs work on the same target, it is reasonable to conclude that the HBVr risk for sarilumab is similar to that of tocilizumab. Indeed, when used at recommended doses for COVID-19 or RA treatment, both drugs have similar IL-6R occupancy and clinical activity [55]. Siltuximab (antibody against IL-6 itself) is another agent blocking the same pathway which has been used to treat COVID-19 [56]. Although HBVr has been reported after siltuximab treatment for COVID-19 [40], the exact risk is not known in COVID or RA patients.

**Tofacitinib**

Tofacitinib is an oral selective inhibitor of JAK1 and JAK3. It modulates the actions of interferons and IL-6 and suppresses cytokine production, thereby attenuating progressive lung injury from COVID-19 pneumonia [20]. JAK signaling is also involved in the immune response in CHB and its inhibition may impair interferon-mediated suppression of viral replication [57, 58]. There are no data on HBVr following tofacitinib for treatment of COVID-19. However, three RA studies report on HBVr with tofacitinib (Table 2): one small study from the US (n = 6) and two larger studies from Taiwan (n = 81 and n = 72) [59–61]. Both Taiwanese studies (using similar HBVr definitions) reported a high reactivation rate of 33–50% after receiving tofacitinib in HBsAg-positive patients not taking HBV antiviral prophylaxis. Again, no HBsAg-positive patient taking NA prophylaxis developed HBVr. Among HBsAg-negative/anti-HBc-positive patients, two of the three studies detected no cases of HBVr while Wang et al. described HBVr in 3.1% of patients not receiving NA prophylaxis [59–61]. Therefore, like tocilizumab, the HBVr risk from tofacitinib seems to be high (> 10%) in HBsAg-positive patients and moderate (1–10%) for HBsAg-negative, anti-HBc-positive patients.

**Baricitinib**

In Rodriguez-Tajes et al.’s study specific to COVID-19, no HBVr was seen in the two patients on baricitinib, but both were receiving NA prophylaxis (Table 2) [40]. In post-hoc analysis of a multi-national cohort from phase III clinical trials of baricitinib in 2890 patients with RA, there were 215 HBsAg-negative, anti-HBc-positive patients [62]. Of these, four (1.9%) met the study’s definition for HBVr (new appearance of HBV DNA to ≥ 100 IU/mL) with HBV DNAs ranging from 256 to 1547 IU/mL. However, a total of 32/215 (14.9%) patients were HBV DNA positive at some point during follow-up (24/32 below the lower limit of detection of 29 IU/mL). Therefore, the rate of HBVr in HBsAg-negative/anti-HBc-positive patients can as high as 14.9% if the definition of any detectable HBV DNA is used which is the case in most studies. Reassuringly, none of these patients developed ALT elevations and only three required antiviral therapy.

**Caution with interpreting and applying HBVr data to COVID-19**

Several limitations should be considered when interpreting and applying the above results to the COVID-19 setting. First, aside from Rodriguez-Tajes et al.’s Spanish study, there are no other data specific to COVID-19 patients. Instead, HBVr risk is extrapolated from RA patients receiving the same immunosuppressive drugs. Clearly COVID-19 and RA are two different disease processes and their treatment regimens differ. Although these drugs are typically used in combination with corticosteroids or other immunosuppressive drugs in both conditions, the cumulative exposure is much higher in RA patients. For example, in COVID-19, IL-6R antibodies are recommended as single infusions while the JAK inhibitors are recommended for a duration of 14 days [10]. In RA, these drugs may be continued for prolonged periods while they still maintain disease control. Furthermore, use of these biological or targeted synthetic DMARDs in RA patients usually comes after failing to achieved remission with months of conventional synthetic DMARD therapy which also carry a risk of HBVr. Second, even the RA literature regarding HBVr is limited to mostly small single-center studies. Almost all studies are retrospective in nature which may rely on incomplete data, especially HBV DNA and serology, if regular testing is not protocolised post-DMARD therapy [63]. Third, although pooled data from existing small studies can provide more meaningful information, this is made difficult or less accurate by slightly different definitions of
HBVr applied in each study which can over- or underestimate the true HBVr rate. Indeed, only four of the 16 studies listed in Table 2 had adopted a definition provided by international liver societies such as the AASLD or APASL guidelines (which themselves differ in their definition of HBVr) [64, 65]. Importantly, no HBVr has been reported in patients receiving NA prophylaxis, regardless of the definition used. For these reasons, caution needs to be exercised when estimating HBVr risk in COVID-19 following immunosuppressive therapies. Nonetheless, the above data provides clinicians some appreciation of this risk to determine which patients require NA prophylaxis.

**Antiviral prophylaxis in CHB patients receiving COVID-19 therapies (Fig. 1)**

In HBsAg-positive patients with COVID-19, elevation of serum transaminase levels may be either secondary to HBV or COVID-19 [4]. COVID-19 immunosuppressive therapies (high-dose corticosteroids, tocilizumab/sarilumab, baricitinib and/or tofacitinib) may result in HBV reactivation, hepatitis flare and acute liver failure in patients with current HBV infection [39, 62, 63]. Therefore, antiviral prophylaxis is strongly recommended in all HBsAg-positive patients with severe COVID-19 during corticosteroid and other immunosuppressive therapy [22]. The current recommended first-line NAs with high barrier to resistance (i.e. entecavir or tenofovir) should be used for antiviral prophylaxis [12]. The duration of prophylactic NA treatment commenced for patients undergoing immunosuppression is usually 6–12 months after cessation of the immunosuppressive agent(s) [12, 39]. However, virologic and even biochemical relapses commonly occur in CHB patients after stopping NA treatment before HBsAg seroclearance [66, 67]. Therefore, ongoing monitoring of ALT, HBsAg and HBV DNA is recommended after NA withdrawal. In the absence of immunosuppressive therapy, it would also be reasonable to initiate antiviral therapy for HBV whenever the patients fulfill the treatment criteria recommended by international guidelines, namely HBV DNA > 2,000 IU/mL, ALT > upper limit of normal (ULN) (EASL) [68] or 2xULN (AASLD, APASL) [64, 65]. HBsAg-positive patients should also undergo (non-invasive) fibrosis assessment with treatment considered in those with advanced fibrosis or cirrhosis and detectable HBV DNA [12]. If long term therapy is required, the current first-line NAs all have excellent long-term safety [69].

For COVID-19 patients who are HBsAg-negative and anti-HBc-positive, HBV DNA should be checked (for OBI) if corticosteroids and other potent immunosuppressive therapies are anticipated and antiviral therapy with entecavir or tenofovir should be considered if HBV DNA becomes detectable. Monitoring of liver enzymes and repeating HBsAg and HBV DNA at the time of elevation of transaminases would suffice [70].

**Conclusion**

COVID-19 and current or past HBV infection coexist in a substantial number of people worldwide. With the rapid evolution of COVID-19 treatment, the implications of immunosuppressive regimens on the risk of HBVr must
be considered. From the rheumatology experience, there is a high risk of (often serious) HBVr with corticosteroids, IL-6 agents and JAK inhibitors in HBsAg-positive patients. NA prophylaxis is highly effective and recommended in these patients. In past HBV infection, the risk of HBVr is low-moderate and usually not clinically significant. While NA prophylaxis is not generally advised, close monitoring is required. Given the limitations in extrapolating these data, more studies are required to clarify the risk of HBVr with these agents in the context of COVID-19.

Authors’ contributions All authors were responsible for the study concept and design. All authors had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. All authors were responsible for the interpretation of data, the drafting, and critical revision of the manuscript for important intellectual content. All authors approved the final version of the article.

Funding This work was partly supported by the Health and Medical Research Fund (HMRF) – Food and Health Bureau Commissioned Research on COVID-19 (Reference no.: COVID1903002) granted to Grace Wong.

Declarations

Conflict of interest Ken Liu and Madeleine Gill declare no conflict of interest. Terry Yip has served as an advisory committee member and a speaker for Gilead Sciences. Grace Wong has served as an advisory committee member for Gilead Sciences and Janssen, and as a speaker for Abbott, Abbvie, Ascleits, Bristol-Myers Squibb, Echosens, Gilead Sciences, Janssen and Roche. She has also received a research grant from Gilead Sciences.

References

1. World Health Organization. Weekly epidemiological update on COVID 19 - 19 October 2021. https://www.who.int/publicatio ns/m/item/weekly-epidemiological-update-on-covid-19---19-october-2021. Accessed October 20, 2021.
2. Global Hepatitis Report 2017. Geneva: World Health Organisation; 2017. Licence: CCBY-NC-SA 3.0 IGO.
3. He Q, Zhang G, Gu Y, Wang J, Tang Q, Jiang Z, et al. Clinical characteristics of COVID-19 patients with pre-existing hepatitis B virus infection: a multicenter report. Am J Gastroenterol. 2021;116(2):420–421
4. Yip TC, Wong VW, Lui GC, Chow VC, Tse YK, Hui VW, et al. Current and past infections of HBV do not increase mortality in patients with COVID-19. Hepatology. 2021;74(4):1750–1765
5. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708–1720
6. Chen J, Qi T, Liu L, Ling Y, Qian Z, Li T, et al. Clinical progression of patients with COVID-19 in Shanghai. China J Infect. 2020;80(5):e1–e6
7. Li Y, Li C, Wang J, Zhu C, Zhu L, Ji F, et al. A case series of COVID-19 patients with chronic hepatitis B virus infection. J Med Virol. 2020;92(11):2785–2791
8. Zou X, Fang M, Li S, Wu L, Gao B, Gao H, et al. Characteristics of liver function in patients with SARS-CoV-2 and chronic HBV coinfection. Clin Gastroenterol Hepatol. 2021;19(3):597–603
9. Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA. 2020;323(20):2052–2059
10. COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health. Available at https://covid19treatmentguidelines.nih.gov/. Accessed 18 Oct 2021.
11. Lombo R, Liang TJ. Hepatitis B reactivation associated with immune suppressive and biological modifier therapies: current concepts, management strategies, and future directions. Gastroenterology. 2017;152(6):1297–1309
12. Lau G, Yu ML, Wong G, Thompson A, Ghazianian H, Hou JL, et al. APASL clinical practice guideline on hepatitis B reactivation related to the use of immunosuppressive therapy. Hep Int. 2021;15(5):1031–1048
13. Scobie HM, Johnson AG, Suthar AB, Severson R, Alden NB, Balter S, et al. Monitoring Incidence of COVID-19 Cases, Hospitalizations, and Deaths, by Vaccination Status - 13 U.S. Jurisdictions, April 4–July 17, 2021. MMWR Morb Mortal Wkly Rep. 2021;70(37):1284–90.
14. Garg S, Kim L, Whitaker M, Acosta AM, Pham H, Whitaker M, et al. Hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed coronavirus disease 2019—COVID-19 NET, 14 states, March 1–30, 2020. MMWR Morb Mortal Wkly Rep. 2021;69(15):458–464
15. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2021;397(10285):1637–45.
16. Benfield T, Bodilsen J, Brielhe G, Harboe ZB, Helleberg M, Holm C, et al. Improved survival among hospitalized patients with COVID-19 treated with remdesivir and dexamethasone. A nationwide population-based cohort study. Clin Infect Dis. 2021.
17. Kalil AC, Patterson TF, Mehta AK, Tomashek KM, Wolfe CR, Ghazaryan V, et al. Baricitinib plus remdesivir for hospitalized adults with COVID-19. N Engl J Med. 2021;384(9):795–807
18. Veiga VC, Prats J, Fairass DL, Rosa RG, Dourado LD, Zampieri FG, et al. Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial. BMJ. 2021;372:n84
19. REMAP-CAP Investigators GA, Mouncey PR, et al. Interleukin-6 Receptor Antagonists in Critically Ill Patients with COVID-19: An International, Multicenter, Randomized, Controlled Trial. New England Journal of Medicine. 2021;384(16):1491–502.
20. Guimarães PO, Quirk D, Furtado RH, Maia LN, Saraiva JF, Antunes MO, et al. Tofacitinib in patients hospitalized with COVID-19 pneumonia. N Engl J Med. 2021;385(5):406–415
21. Baber S, et al. Monitoring Incidence of COVID-19 Cases, Hospitalizations, and Deaths, by Vaccination Status - 13 U.S. Jurisdictions, April 4–July 17, 2021. MMWR Morb Mortal Wkly Rep. 2021;70(37):1284–90.
22. Wong GL, Wong VW, Thompson A, Jia J, Hou J, Lesmana CRA, et al. COVID-19: combining antiviral and anti-inflammatory treatments. Lancet Infect Dis. 2020;20(4):400–402
23. Wong GL, Wong VW, Thompson A, Jia J, Hou J, Lesmana CRA, et al. Management of patients with liver derangement during the COVID-19 pandemic: an Asia-Pacific position statement. Lancet Gastroenterol Hepatol. 2020;5(8):776–787
24. Bertolini A, van de Peppel IP, Bodewes F, Moschate H, Fantin A, Farinati F, et al. Abnormal liver function tests in patients with COVID-19: relevance and potential pathogenesis. Hepatology. 2020;27(5):1864–1872
25. Yip TC, Lui GC, Wong VW, Chow VC, Ho TH, Li TC, et al. Liver injury is independently associated with adverse clinical outcomes in patients with COVID-19. Gut. 2021;70(4):733–742
26. Cai Q, Huang D, Yu H, Zhu Z, Xia Z, Su Y, et al. COVID-19: abnormal liver function tests. J Hepatol. 2020;73(3):566–574
26. Marjot T, Webb GJ, Barratt AS, Moon AM, Stamatakis Z, Wong VW, et al. COVID-19 and liver disease: mechanistic and clinical perspectives. Nat Rev Gastroenterol Hepatol. 2021;18(5):348–64.

27. Lv Y, Zhao X, Wang Y, Zhu J, Ma C, Feng X, et al. Abnormal Liver Function Tests Were Associated With Adverse Clinical Outcomes: An Observational Cohort Study of 2,912 Patients With COVID-19. Front Med (Lausanne). 2021;8:639855.

28. Balderremo D, Mattos AZ, Mulqui V, Chiesa T, Placido-Damian Z, Abarca J, et al. Abnormal liver tests during hospitalization predict mortality in patients with COVID-19: a multicenter study from South America. Can J Gastroenterol Hepatol. 2021;2021:1622533.

29. Middleton P, Hsu C, Lythgoe MP. Clinical outcomes in COVID-19 and cirrhosis: a systematic review and meta-analysis of observational studies. BMJ Open Gastroenterol. 2021;8(1).

30. Hippisley-Cox J, Coupland CA, Mehta N, Keogh RH, Diaz-Ordaz K, Khunti K. et al. Risk prediction of covid-19 related death and hospital admission in adults after covid-19 vaccination: national prospective cohort study. BMJ. 2021;374:n2244.

31. Ding ZY, Li GX, Chen L, Shu C, Song J, Wang W, et al. Association of liver abnormalities with in-hospital mortality in patients with COVID-19. J Hepatol. 2021;74(6):1295–1302.

32. Chen L, Huang S, Yang J, Cheng X, Shang Z, Lu H, et al. Clinical characteristics in patients with SARS-CoV-2/HBV co-infection. J Viral Hepat. 2020;27(12):1504–1507.

33. Liu R, Zhao L, Cheng X, Han H, Li C, Li D, et al. Clinical characteristics of COVID-19 patients with hepatitis B virus infection - a retrospective study. Liver Int. 2021;41(4):720–730.

34. Kang SH, Cho DH, Choi J, Baik SK, Gwon JG, Kim MY. Association between chronic hepatitis B infection and COVID-19 outcomes: A Korean nationwide cohort study. PLoS One. 2021;16(10):e0258229.

35. Sodeifian F, Seyedalhosseini ZS, Kian N, Eftekhari M, Najari, et al. Drug-Induced Liver Injury in COVID-19 Patients: A Systematic Review. Front Med (Lausanne). 2021;8:731436.

36. Wong GL, Yip TC, Dong Y, Li X, Yu Y, Lv F, et al. JAK/STAT signaling is involved in IL-35-induced inhibition of hepatitis B virus infection: pilot evaluation study. J Clin Rheumatol. 2016;22(7):364–368

37. Wong GL, Yuen BW, Chen HL, Tse YK, Yip TC, Lam KL, et al. Impact of dose and duration of corticosteroid on the risk of hepatitis flare in patients with chronic hepatitis B. Liver Int. 2019;39(2):271–279.

38. Wong GL, Wang VW, Yuen BW, Tse YK, Yip TC, Luk HW, et al. Risk of hepatitis B surface antigen seroconversion after corticosteroid treatment in patients with previous hepatitis B virus exposure. J Hepatol. 2020;72(1):57–66.

39. Hösel M, Quasdorff M, Wiegmann K, Webb D, Zedler U, Broxtermann M, et al. Not interferon, but interleukin-6 controls early gene expression in hepatitis B virus infection. Hepatology. 2009;50(6):1773–1782.

40. Biehl A, Harinstein L, Brinker A, Glaser R, Munoz M, Avigan M. A case series analysis of serious exacerbations of viral hepatitis and non-viral hepatic injuries in tocilizumab-treated patients. Liver Int. 2021;41(3):515–528.

41. Sonneveld MJ, Murad SD, van der Eijk AA, de Man RA. Fulminant liver failure due to hepatitis B reactivation during treatment with tocilizumab. ACG Case Rep J. 2019;6(12):e00243.

42. Chen LF, Mo YQ, Jing J, Ma JD, Zheng DH, Dai L. Short-course tocilizumab increases risk of hepatitis B virus reactivation in patients with rheumatoid arthritis: a prospective clinical observation. Int J Rheum Dis. 2017;20(7):859–869.

43. Kuo MH, Tseng CW, Lu MC, Tung CH, Tseng KC, Huang KY, et al. Risk of Hepatitis B Virus Reactivation in Rheumatoid Arthritis Patients Undergoing Tocilizumab-Containing Treatment. Dig Dis Sci. 2021.

44. Chen M-H, Chen M-H, Liu C-Y, Tsai C-Y, Huang D-F, Lin H-Y, et al. Hepatitis B virus reactivation in rheumatoid arthritis patients undergoing biologics treatment. J Infect Dis. 2016;215(4):566–573.

45. Campbell C, Andersson MI, Ansari MA, Moswela O, Misbah SA, Klenerman P, et al. Risk of Reactivation of Hepatitis B Virus (HBV) and Tuberculosis (TB) and Complications of Hepatitis C Virus (HCV) Following Tocilizumab Therapy: A Systematic Review to Inform Risk Assessment in the COVID-19 Era. Front Med (Lausanne). 2021;8:706482.

46. Fukuda W, Hanyu T, Katayama M, Mizuki S, Okada A, Miyata M, et al. Risk stratification and clinical course of hepatitis B virus reactivation in rheumatoid arthritis patients with resolved infection: final report of a multicenter prospective observational study at Japanese Red Cross Hospital. Arthritis Res Ther. 2019;21(1):255.

47. Watanabe R, Hashimoto M, Morinobu A. Correspondence on ‘The use of tocilizumab and tofacitinib in patients with resolved hepatitis B infection: a case series’. Ann Rheum Dis. 2020.

48. Schwancke EC, Crone M, Kreissl-Kemmer S, Weissbrich B, Weiss J, Tony HP, et al. Management of anti-HBc-positive patients with rheumatoid arthritis: a case series. Ann Rheum Dis. 2020.

49. Xu C, Rafique A, Potocky T, Paccaly A, Nolain P, Lu Q, et al. Differential binding of sarilumab and tocilizumab to IL-6R and effects of receptor occupancy on clinical parameters. J Clin Pharmacol. 2021;61(5):714–724.

50. Gritti G, Raimondi F, Bottazzi B, Ripamonti D, Riva I, Landi F, et al. Siltuximab downregulates interleukin-8 and pentraxin 3 to improve ventilatory status and survival in COVID-19. Leukemia. 2021;35(9):2710–2714.

51. Boor PPC, de Ruiter PE, Aasmawidjaja PS, Lubberts E, van der Laan LJW, Kwakkeboom J. JAK-inhibitor tofacitinib suppresses interferon alfa production by plasmacytoid dendritic cells and inhibits antigenic and antiviral effects of interferon alfa. Transl Res. 2017;188:67–79.

52. Dong Y, Li X, Yu Y, Lv F, Chen Y. JAK/STAT signaling is involved in IL-35-induced inhibition of hepatitis B virus
antigen-specific cytotoxic T cell exhaustion in chronic hepatitis B. Life Sciences. 2020;252:117663.

59. Chen YM, Huang WN, Wu YD, Lin CT, Chen YH, Chen DY, et al. Reactivation of hepatitis B virus infection in patients with rheumatoid arthritis receiving tocilizumab: a real-world study. Ann Rheum Dis. 2018;77(5):780–782

60. Serling-Boyd N, Mohareb AM, Kim AY, Hyle EP, Wallace ZS. The use of tocilizumab and tocilizumab in patients with resolved hepatitis B infection: a case series. Ann Rheum Dis. 2021;80(2):274–276

61. Wang ST, Tseng CW, Hsu CW, Tung CH, Huang KY, Lu MC, et al. Reactivation of hepatitis B virus infection in patients with rheumatoid arthritis receiving tocilizumab. Int J Rheum Dis. 2021.

62. Harigai M, Winthrop K, Takeuchi T, Hsieh TY, Chen YM, Smolen JS, et al. Evaluation of hepatitis B virus in clinical trials of baricitinib in rheumatoid arthritis. RMD Open. 2020;6(1).

63. Mohareb AM, Patel NJ, Fu X, Kim AY, Wallace ZS, Hyle EP. Screening for hepatitis B virus prior to initiating tocilizumab and tocilizumab in patients with rheumatologic diseases: a cross-sectional study. J Rheumatol. 2021.

64. Terrault NA, Lok ASF, McMahon BJ, Chang KM, Hwang JP, Jonas MM, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67(4):1560–1599

65. Sarin SK, Kumar M, Lau GK, Abbas Z, Chan HL, Chen CJ, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hep Int. 2016;10(1):1–98

66. Wong GL, Chan HL, Yuen BW, Tse YK, Luk HW, Yip TC, et al. The safety of stopping nucleos(t)ide analogue treatment in patients with HBeAg-negative chronic hepatitis B. Liver Int. 2020;40(3):549–557

67. Yip TC, Wong GL, Wong VW, Tse YK, Lui GC, Lam KL, et al. Durability of hepatitis B surface antigen seroclearance in untreated and nucleos(t)ide analogue-treated patients. J Hepatol. 2017.

68. European Association for the Study of the Liver. Electronic address eee, European Association for the Study of the L. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67(2):370–98

69. Wong GL, Seto WK, Wong VW, Yuen MF, Chan HL. Review article: long-term safety of oral anti-viral treatment for chronic hepatitis B. Aliment Pharmacol Ther. 2018;47(6):730–737

70. Yip TC, Wong GL. Current knowledge of occult hepatitis B infection and clinical implications. Semin Liver Dis. 2019;39(2):249–260

71. Nakamura J, Nagashima T, Nagatani K, Yoshio T, Iwamoto M, Minota S. Reactivation of hepatitis B virus in rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs. Int J Rheum Dis. 2016;19(5):470–475

72. Lin CT, Huang WN, Hsieh CW, Chen YM, Chen DY, Hsieh TY, et al. Safety and effectiveness of tocilizumab in treating patients with rheumatoid arthritis - a three-year study in Taiwan. J Microbiol Immunol Infect. 2019;52(1):141–150

73. Watanabe T, Fukae J, Fukaya S, Sawamukai N, Isobe M, Matsushashi M, et al. Incidence and risk factors for reactivation from resolved hepatitis B virus in rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs. Int J Rheum Dis. 2019;22(4):574–582

74. Ahn SS, Jung SM, Song JJ, Park YB, Park JY, Lee SW. Safety of tocilizumab in rheumatoid arthritis patients with resolved hepatitis B virus infection: data from real-world experience. Yonsei Med J. 2018;59(3):452–456

75. Mok CC, Chan KY, Lee KL, Tam LS, Lee KW. Factors associated with withdrawal of the anti-TNFα biologics in the treatment of rheumatic diseases: data from the Hong Kong Biologics Registry. Int J Rheum Dis. 2014;17(Suppl 3):1–8

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.